Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BLFS 
BioLife Solutions Inc (BLFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BLFS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.3
1 Year Target Price $31.3
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.03% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.22B USD | Price to earnings Ratio - | 1Y Target Price 31.3 |
Price to earnings Ratio - | 1Y Target Price 31.3 | ||
Volume (30-day avg) 9 | Beta 1.76 | 52 Weeks Range 19.10 - 29.55 | Updated Date 08/29/2025 |
52 Weeks Range 19.10 - 29.55 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.03 | Actual -0.33 |
Profitability
Profit Margin -5.92% | Operating Margin (TTM) -4.41% |
Management Effectiveness
Return on Assets (TTM) -0.8% | Return on Equity (TTM) -5.66% |
Valuation
Trailing PE - | Forward PE 250 | Enterprise Value 1135848203 | Price to Sales(TTM) 13.03 |
Enterprise Value 1135848203 | Price to Sales(TTM) 13.03 | ||
Enterprise Value to Revenue 12.15 | Enterprise Value to EBITDA 65.13 | Shares Outstanding 47905300 | Shares Floating 39407829 |
Shares Outstanding 47905300 | Shares Floating 39407829 | ||
Percent Insiders 2.13 | Percent Institutions 104.31 |
Upturn AI SWOT
BioLife Solutions Inc
Company Overview
History and Background
BioLife Solutions, Inc. was founded in 1997. It focuses on developing, manufacturing, and marketing biopreservation tools for cells and tissues. Initially concentrating on blood storage, it evolved to serve the broader cell and gene therapy market through acquisitions and organic growth.
Core Business Areas
- Biopreservation Media: Develops and markets proprietary biopreservation media such as CryoStoru00ae and HypoThermosolu00ae used to preserve cells and tissues during freezing and thawing processes.
- Thawing Devices: Provides automated thawing devices such as the ThawSTARu00ae platform to standardize and optimize the thawing process for cryopreserved biologics.
- Cryopreservation Equipment: Offers controlled-rate freezers and other equipment for cryopreservation applications
- Storage and Cold Chain: Provides cold chain services, including storage and transport of biological materials.
Leadership and Structure
Mike Rice is the CEO. The company has a board of directors that oversees strategic direction. The organizational structure is functional, with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- CryoStor: CryoStor is a line of cryopreservation media used to protect cells during freezing. Competitors include STEMCELL Technologies and Corning. Market share for biopreservation media is fragmented.
- HypoThermosol: HypoThermosol is a preservation media used for cells and tissues at hypothermic temperatures (2-8u00b0C). Competitors include STEMCELL Technologies and Corning. Market share for biopreservation media is fragmented.
- ThawSTAR: ThawSTAR is an automated thawing system. Competitors include Barkey and Asymptote. Market share data is not easily available
Market Dynamics
Industry Overview
The biopreservation market is driven by the growth of cell and gene therapy, regenerative medicine, and biobanking. It is expanding as the need for cell and tissue preservation increases due to these innovative therapies.
Positioning
BioLife Solutions is positioned as a key provider of biopreservation tools for cell and gene therapy. Its competitive advantage lies in its established reputation and integrated portfolio of products.
Total Addressable Market (TAM)
The global biopreservation market is projected to reach billions of dollars. BioLife Solutions is positioned to capture a significant portion of this TAM through its diverse product offerings and market presence.
Upturn SWOT Analysis
Strengths
- Proprietary biopreservation media
- Established customer base in cell and gene therapy
- Integrated portfolio of products
- Strong brand reputation
- Acquisition strategy
Weaknesses
- Reliance on cell and gene therapy market growth
- Competition from larger players with broader portfolios
- Potential for product obsolescence due to technological advancements
- Fluctuations in demand due to clinical trial outcomes
Opportunities
- Expansion into new geographic markets
- Development of new biopreservation technologies
- Partnerships with cell and gene therapy companies
- Increased adoption of biopreservation in research and clinical applications
Threats
- Regulatory changes affecting cell and gene therapy
- Economic downturn impacting research and development budgets
- Emergence of disruptive technologies
- Competition from lower-cost alternatives
Competitors and Market Share
Key Competitors
- STEM
- CCRD
- VWR
Competitive Landscape
BioLife Solutions has a competitive advantage in its biopreservation products and thawing systems. However, it faces competition from larger, more diversified companies.
Major Acquisitions
SAVSU Technologies
- Year: 2020
- Acquisition Price (USD millions): 73
- Strategic Rationale: Expanded cold chain and logistics capabilities.
Global Cooling
- Year: 2021
- Acquisition Price (USD millions): 189
- Strategic Rationale: Added Stirling Ultracold freezers to the portfolio.
Growth Trajectory and Initiatives
Historical Growth: BioLife Solutions has experienced significant revenue growth through organic expansion and acquisitions.
Future Projections: Analysts project continued growth in revenue, driven by the expansion of the cell and gene therapy market. Refer to analyst reports.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand its product portfolio and geographic reach.
Summary
BioLife Solutions is a key player in the biopreservation market, driven by the expanding cell and gene therapy sector. Its integrated product offerings and strategic acquisitions have fueled growth. Key risks include reliance on market growth and competition from larger players. The company should continue investing in innovation to maintain its competitive edge and pursue further strategic acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Financial news sources
- Analyst reports
- Industry reports
Disclaimers:
Financial data and market share information are subject to change. This analysis is for informational purposes only and does not constitute financial advice. Always consult with a qualified financial advisor before making any investment decisions. Values listed are estimates and are not guaranteed to be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLife Solutions Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1989-11-22 | CEO & Chairman Mr. Roderick de Greef | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 159 | Website https://www.biolifesolutions.com |
Full time employees 159 | Website https://www.biolifesolutions.com | ||
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.